Short answer
CapsoVision, Inc (CV) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $4M with net income of −$8M.
Q3 2025 key financials · XBRL
- Revenue
- $4M
- −42.0% QoQ
- Net income
- −$8M
- +20.8% QoQ
- Operating margin
- -226.7%
- Gross margin
- 54.1%
- EPS (diluted)
- $3.44
- +176.6% QoQ
Source: XBRL data from the CapsoVision, Inc (CV) Q3 2025 10-Q on SEC EDGAR. USD.
CapsoVision, Inc Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: FDA Breakthrough Device Designation submitted for pancreatic cancer capsule endoscopy solution Nov 6, 2025, uncertain eligibility and authorization timing
- Updated regulatory risk: Potential delays in FDA 510(k) clearance for CapsoCam Colon second-generation due to FDA staff reductions and government shutdowns still unresolved
- Material regulatory risk: Dependence on FDA 510(k) clearance for CapsoCam Colon products, with failure causing reputational harm, lost sales, and increased liabilities
- Operational risk: Supply chain concentrated in Asia (Taiwan, Japan) with single-source suppliers, vulnerable to geopolitical, trade, and natural disaster disruptions
- Financial risk: Cash $17.8M as of Sep 30, 2025; substantial doubt as going concern; requires further capital raises risking dilution and impacting business continuity
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CapsoVision, Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.